Glaxo sells 4 drugs to Aspen for 170 mln pounds
LONDON (Reuters) - GlaxoSmithKline Plc (GSK.L) has sold four of its older drugs to a unit of South Africa's Aspen Pharmacare Holdings (APNJ.J) for 170 million pounds ($339 million), the world's second biggest drugmaker said on Monday.
The medicines involved are Eltroxin, a thyroid hormone for hyperthyroidism; Lanoxin, a cardiac glycoside for heart failure; Imuran, an immunosuppressant; and Zyloric, an enzyme inhibitor for the treatment of gout.
Aspen will own the four drugs in all major markets outside of the United States, except for rights to Zyloric in Japan.
The products largely no longer hold patent protection and last year recorded sales of around 80 million pounds in the markets concerned.
Glaxo said it would record a gain on the sale in the quarter ended June 30 but the company's earnings per share guidance for the year remains unchanged.
(Reporting by Ben Hirschler)
- Mexican train derails, stranding 1,300 migrants headed toward U.S.
- At least four servicemen killed in eastern Ukraine |
- Man charged with killing six members of same Texas family |
- Taliban sympathizer posts pictures of smiling Bowe Bergdahl
- Israel presses on with Gaza offensive, Palestinians fire rockets |